Group 1 - The company has decided to cancel the supervisory board to enhance governance and protect the rights of stakeholders, with the audit committee taking over its responsibilities [1][2] - The supervisory board members have been recognized for their diligent work and contributions to the company's governance during their tenure [2] Group 2 - The company plans to revise its articles of association and will submit these changes for shareholder approval, with the revised articles disclosed on the Shanghai Stock Exchange website [3] - The company will also handle the necessary business registration changes related to the amendments to its articles of association [3] Group 3 - The company is updating and creating internal governance systems to comply with legal regulations and improve governance, with several new and revised systems approved by the board [4] - Specific internal governance systems, such as the internal audit and control systems, have been reviewed and approved, while others will require shareholder approval [4]

Core Viewpoint - Zhejiang Yinlun Machinery Co., Ltd. has extended the validity period of the resolution for its subsidiary to publicly issue shares to unspecified qualified investors and list on the Beijing Stock Exchange, ensuring continuity in the issuance process [2][6][7]. Group 1: Board Meeting Resolutions - The board meeting was held on December 12, 2025, with all 9 directors present, and the meeting was deemed legal and effective [1][2]. - The resolution to extend the validity period for the subsidiary's public share issuance was passed unanimously with 100% approval [2][4]. - The resolution will be submitted for review at the company's third extraordinary general meeting of shareholders in 2025 [3][6]. Group 2: Upcoming Shareholder Meeting - The third extraordinary general meeting of shareholders is scheduled for December 30, 2025, with a registration date of December 24, 2025 [10][12]. - The meeting will combine on-site voting and online voting, allowing shareholders to participate remotely [10][11]. - The proposals for the meeting have been approved by the board and will be disclosed in relevant announcements [11][10]. Group 3: Capital and Business Scope Changes - The company has completed the registration changes for its capital and business scope, receiving a new business license [29][30]. - The registered capital is now 843,365,301 yuan, and the business scope includes manufacturing automotive parts, cooling equipment, cloud computing devices, and various other technological products [29][30].

来源：洛阳钼业 在分红方面，公司多次承诺，2024-2026年连续三年现金分红占当年归母净利润比例超40%，以实际行 动回馈股东。 秉持公开、坦诚、透明等原则，洛阳钼业近年来搭建起完善的海内外传播平台——官方微信、官方网 站、东方财富号、同顺号、抖音号、视频号、Facebook、X、领英、Youtube等，并第一时间向公众传递 经营、品牌、ESG等相关信息。 此外，随着多位行业精英加入，洛阳钼业核心管理团队全部落位，下阶段将按既定战略继续有序推进管 理机制变革、精细化运营管理等命题，目标是建立精益运营的生产方式，打造全球性的平台型组织，驱 动新一轮高速增长。 除了权威财经媒体，洛阳钼业近期也频获市场认可。洛阳钼业稍早前被首次纳入到富时中国A50指数， 并已是上证50指数、沪深300指数和中证全指的成分股。在Mining.com截至9月30日的最新全球矿企（市 值）50强排名中，洛阳钼业上升至第12位，在中国矿业公司中排名第二。 近日，洛阳钼业荣获南方财经全媒体集团·21世纪经济报道颁发的"2025年度卓越董事会"奖。与此同 时，洛阳钼业还获得智通财经颁发的2025精英董秘奖，《证券市场周刊》金曙光·ESG实践 ...

Core Viewpoint - Supor announced that non-independent director Mr. Su Xianze has resigned from his position on the eighth board of directors and as the chairman of the strategic committee due to personal reasons. The company will promptly complete the director replacement process as required by relevant laws and regulations [1] Group 1 - Mr. Su Xianze will be appointed as the honorary chairman of the company to continue leveraging his expertise in strategic decision-making, industry resources, and influence [1] - The honorary chairman role does not carry the rights and obligations associated with the positions of director and chairman as defined by the Company Law and the company's articles of association [1] - The main responsibilities of the honorary chairman include providing professional guidance and advice on the company's strategic development, major decisions, and brand building [1]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has released the draft of the "Regulations on the Supervision and Administration of Listed Companies," marking the first administrative regulation for listed company supervision in China, aimed at enhancing governance, information disclosure, mergers and acquisitions, and investor protection [1][7]. Group 1: Governance Requirements - The draft establishes a dedicated chapter on corporate governance, focusing on the governance structure, articles of association, and the roles of controlling shareholders and executives, thereby enhancing accountability and oversight [2][7]. - It emphasizes the responsibilities of independent directors and the board secretary, aiming to strengthen internal supervision mechanisms within companies [2][7]. Group 2: Mergers and Acquisitions - The draft enhances support for mergers and acquisitions by clarifying definitions, qualifications for acquirers, and disclosure standards for equity changes, while also refining the requirements and procedures for major asset restructurings [3][7]. - It aims to ensure that financial advisors play a crucial role in overseeing mergers and acquisitions, thereby facilitating industry upgrades [3][7]. Group 3: Combating Illegal Activities - The draft intensifies the crackdown on illegal activities, particularly financial fraud, by reinforcing regulations on related-party transactions and requiring companies to establish robust internal control systems [4][5]. - It prohibits major shareholders from misappropriating company funds and sets legal responsibilities for those involved in fraudulent activities, aiming to dismantle the "ecosystem" of fraud [4][5]. Group 4: Investor Protection - A dedicated chapter on investor protection is included, mandating companies to enhance investment value and prevent market manipulation, while also improving cash dividend and share buyback mechanisms [6][7]. - The draft requires companies undergoing voluntary delisting to provide cash options or other legal measures to protect dissenting shareholders [6][7]. Group 5: Timeliness of Regulation - The introduction of the draft is timely, given the increasing number of listed companies in China and the need for improved governance and oversight mechanisms to enhance company quality [7]. - The draft aims to fill the regulatory gap between existing laws and the rules set by the CSRC and stock exchanges, promoting high-quality development of listed companies [7].

Core Viewpoint - The resignation of Jiang Yi, the chairman of Zhejiang Kang En Bei Pharmaceutical Co., has raised concerns about the company's internal governance and strategic continuity amid poor performance and a long-term decline in stock price [1][7]. Group 1: Frequent Personnel Changes and Governance Stability - Jiang Yi's departure is attributed to "work adjustment," but details are lacking, leading to questions about governance stability [2]. - His tenure was brief, having joined the board at the end of 2023 and becoming chairman in August 2024, only to resign in December 2025, indicating a lack of long-term succession planning [2][8]. - The market is concerned about whether the successor can maintain the established strategy and how decision-making will remain coherent during the transition [2][8]. Group 2: Weak Financial Growth and Core Profitability Pressure - For the first three quarters of 2025, the company's revenue grew only 1.27% year-on-year, indicating stagnation [3][9]. - The growth in net profit is largely driven by non-recurring gains, with the growth rate of net profit excluding non-recurring items at just 1.61%, showing limited improvement in core profitability [3][9]. - The company's revenue compound annual growth rate over the past three years is approximately -1%, with a concerning long-term decline in gross margin from 77.11% in 2018 to 53.14% in 2024 [3][9]. Group 3: Strategic Implementation Challenges - The company claims to adhere to a "one body, two wings" strategy, focusing on traditional Chinese medicine, chemical drugs, and health consumer products, but the chemical drug segment has seen a decline [4][10]. - The stock price has remained low, with a market value that has shrunk by about 80% from its peak, and the stock has underperformed the Shanghai Composite Index by over 16% this year [4][10]. - The failure in market capitalization management, combined with weak performance and unclear governance prospects, has created a negative feedback loop [4][10]. Group 4: Outlook for Rebuilding Trust through Governance - The current crisis presents an opportunity for the company to reshape governance and regain confidence [5][11]. - The company needs to go beyond procedural disclosures and respond transparently to market concerns, detailing the decision-making process during the transition and the qualifications of new board members [5][11]. - Strengthening financial and business disclosures, along with clarifying the path to improving profit quality, is essential for restoring investor relations and transforming the current turmoil into a governance upgrade [5][11].

Core Viewpoint - The board's unanimous vote of "9 in favor, 0 against" is undermined by a notable abstention from director Fan Yongwu, highlighting concerns over a nearly 2 billion yuan cash expenditure amid performance pressures and governance issues at Watson Bio [1][6]. Group 1: Financial Challenges - Watson Bio plans to spend approximately 19.98 billion yuan to acquire a 13.78% stake in its subsidiary Yuxi Watson, despite only reporting a net profit of 1.63 billion yuan for the first three quarters, indicating a cash outflow equivalent to 12 times its quarterly profit [2][8]. - The acquisition involves payments of 16.39 billion yuan to "Huixiang Yuetai" and 3.59 billion yuan to "Tianjin Lanwo," with no expected enhancement in product lines or market expansion, raising concerns about prioritizing cash usage [2][8]. Group 2: Valuation Paradox - The valuation logic of the transaction appears contradictory during a downturn in the vaccine market, with Yuxi Watson's estimated value at around 14.5 billion yuan, while Watson Bio's total market capitalization is only about 19.5 billion yuan [9][10]. - This discrepancy raises questions about whether the subsidiary is overvalued or if the parent company's stock is undervalued, suggesting that a more rational approach would be to repurchase shares rather than overpay for non-tradable subsidiary equity [10]. Group 3: Governance Concerns - The transaction involves complex relationships, with one counterparty, "Huixiang Yuetai," having partners that include members of Watson Bio, suggesting a potential internal transaction [4][10]. - The decision to use scarce cash for a high-valuation acquisition amid uncertain future profitability raises doubts about whether this move is aimed at long-term growth or facilitating exits for specific investors [4][10]. - Watson Bio's history of controversial capital operations, including past attempts to sell subsidiaries at low prices, reflects a governance structure lacking effective control, leading to potential internal management issues [5][11].

Core Viewpoint - Qingdao Beer has been recognized as the "Best Practice Case of the Board of Directors of Listed Companies for 2025" by the China Listed Companies Association, highlighting its effective corporate governance and receiving high recognition from the capital market [1][3]. Group 1: Evaluation Criteria - The evaluation for the awards was based on multiple dimensions including the operation of the board of directors, the performance of directors, ESG responsibility fulfillment, and information disclosure [3]. - The "Best Practice Case" represents the advanced level of corporate governance among listed companies and serves as a model for others [3]. Group 2: Company Achievements - Qingdao Beer, as the first A+H share listed company in China, has actively explored and strengthened its understanding of regulatory frameworks in both mainland China and Hong Kong, establishing a governance structure that aligns with international standards [3]. - The company has developed a diversified shareholding and board structure, creating an effective power balance mechanism that ensures scientific decision-making [3]. - Continuous improvement in the board's construction and operations has led to significant achievements, effectively supporting and promoting the company's high-quality development [3]. Group 3: Future Plans - With the increasing demands for governance quality in the domestic capital market, the company plans to continue implementing the CSRC's "Three-Year Action Plan to Improve the Quality of Listed Companies in Shanghai" and other regulatory requirements [3]. - The company aims to continuously optimize and enhance its corporate governance system to promote standardized operations and value enhancement, positioning itself as a strong engine for high-quality development [3].

Core Points - IMCD N.V. announces the nomination of Mr. Janus Smalbraak for reappointment as Chair of the Supervisory Board at the 2026 AGM, along with Mr. Stephan Nanninga for a third term and Mr. Willem Eelman for a second term [1][2][3][4] Group 1: Nominations and Terms - Janus Smalbraak has been nominated for a fourth and final term of two years as Chair of the Supervisory Board, having first been appointed in 2016 [2] - Stephan Nanninga is nominated for a third term of two years, having first been appointed in 2018 [3] - Willem Eelman is nominated for a second term of four years, having first been appointed in 2022 [4] Group 2: Purpose and Future Plans - The reappointments aim to maintain continuity and leverage accumulated knowledge within the Supervisory Board to support IMCD's management in the coming years [5] - The Supervisory Board intends to expand its composition with a sixth member in 2026, with a search currently ongoing [5] Group 3: Company Overview - IMCD, based in Rotterdam, is a leading global partner in the distribution and formulation of specialty chemicals and ingredients, focusing on sustainable value in the supply chain [6] - In 2024, IMCD reported revenues of EUR 4,728 million and employed over 5,100 staff [7]

Group 1 - The evaluation of "2025 Listed Company Secretary Performance" by the China Listed Companies Association awarded Zhao Junwei, the financial head and board secretary of Zhejiang Jiaokao, the highest rating of "5A" for his outstanding performance [1] - The evaluation aims to enhance the capabilities and professional qualities of company secretaries, promoting overall improvement in corporate governance [1] - A total of 1,571 company secretaries participated, with only 282 achieving the 5A rating, representing 5.10% of the total [1] Group 2 - Zhejiang Jiaokao has established a solid governance framework supported by its controlling shareholder, Zhejiang Transportation Group, focusing on compliance and high standards [1][2] - The company has received multiple awards for best practices in board governance and sustainable development, reflecting its commitment to corporate social responsibility [1] - The company has maintained an AA credit rating from the Zhejiang Provincial Transportation Department for 18 consecutive years and has been recognized as a benchmark enterprise for social responsibility in Zhejiang [2] Group 3 - As a major infrastructure construction enterprise in Zhejiang Province, Zhejiang Jiaokao is aligning with the provincial policy to build a "strong transportation country," developing a primary focus on transportation infrastructure and supplementary areas [3] - The company aims to become a leading comprehensive solution provider in the infrastructure sector, enhancing operational standards and information disclosure quality [3] - Future strategies include strengthening value transmission and market capitalization management while fostering open communication with the capital market to create greater value for shareholders [3]